MARKET

BNTC

BNTC

Benitec Biopharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.920
-0.030
-1.02%
Opening 15:21 12/06 EST
OPEN
2.940
PREV CLOSE
2.950
HIGH
2.940
LOW
2.740
VOLUME
72.01K
TURNOVER
--
52 WEEK HIGH
10.49
52 WEEK LOW
2.300
MARKET CAP
23.86M
P/E (TTM)
-1.0564
1D
5D
1M
3M
1Y
5Y
We're Keeping An Eye On Benitec Biopharma's (NASDAQ:BNTC) Cash Burn Rate
We can readily understand why investors are attracted to unprofitable companies. For example, although...
Simply Wall St. · 11/27 11:54
Benitec reports Q1 results
Benitec (NASDAQ:BNTC): Q1 GAAP EPS of -$0.62. Cash and cash equivalents of $15.72K Press Release
Seekingalpha · 11/15 13:55
Benitec Biopharma Q1 EPS $(0.62) Up From $(2.45) YoY
Benitec Biopharma (NASDAQ:BNTC) reported quarterly losses of $(0.62) per share. This is a 74.69 percent increase over losses of $(2.45) per share from the same period last year.
Benzinga · 11/15 13:29
BRIEF-Benitec Biopharma Reports Q1 2022 Loss Per Share $0.62
reuters.com · 11/15 13:20
Benitec Biopharma Discloses Q1 2022 Financial Results
Benitec Biopharma Inc. (NASDAQ: BNTC) ("Benitec" or "the Company"), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on the proprietary DNA-directed RNA interference ("ddRNAi") platform, today announ...
PR Newswire · 11/15 13:00
26 Stocks Moving in Friday's Pre-Market Session
Gainers
Benzinga · 10/22 11:32
Benitec Biopharma Receives Notice Of Allowance For U.S. Patent Titled 'REAGENTS FOR TREATMENT OF OCULOPHARYNGEAL MUSCULAR DYSTROPHY (OPMD) AND USE THEREOF'
https://patentcenter.uspto.gov/#!/applications/16093493/ifw/docs
Benzinga · 09/22 17:04
Benitec Biopharma Provides Operational Update and Releases its 2021 Fiscal Year-End Financial Results
Benitec Biopharma Inc. (NASDAQ: BNTC) ("Benitec" or "the Company"), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on the proprietary DNA-directed RNA interference ("ddRNAi") platform, today provid...
PR Newswire · 09/20 12:00
More
Forecast
Actual (K USD)
Estimate (K USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of BNTC. Analyze the recent business situations of Benitec Biopharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
0.00%Buy
100.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average BNTC stock price target is 14.00 with a high estimate of 14.00 and a low estimate of 14.00.
High14.00
Average14.00
Low14.00
Current 2.920
EPS
Actual
Estimate
-13.18-9.88-6.59-3.29
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Institutional Holdings
Institutions: 23
Institutional Holdings: 1.65M
% Owned: 20.21%
Shares Outstanding: 8.17M
TypeInstitutionsShares
Increased
4
54.31K
New
5
25.41K
Decreased
2
3.93K
Sold Out
4
73.89K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.98%
Pharmaceuticals & Medical Research
-0.59%
Key Executives
Chairman/Director
Jerel Banks
Chief Executive Officer/Secretary
Gregory West
Chief Financial Officer
Bryan Dulhunty
Chief Scientific Officer
Michael Graham
Secretary
Oliver Kidd
Director
Kevin Buchi
Non-Executive Director
Megan Boston
Non-Executive Director
Peter Francis
Declaration Date
Dividend Per Share
Ex-Div Date
--
Dividend USD 0.002929
06/01/2018
About BNTC
Benitec Biopharma Inc is an Australia-based biotechnology company. The Company is focused on developing a therapeutic technology platform that combines ribonucleic acid (RNA) interference with gene therapy for the goal of silencing disease-causing genes from a single administration. The Company's technology, deoxyribonucleic acid (DNA)-directed RNA interference (ddRNAi), is used to develop product candidates in chronic and life-threatening human disease areas including orphan disease and infectious disease. Its pipeline includes BB-301, and BB-103. The Company's lead product candidate, BB-301, is used for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD). Its BB-103 pipeline product is being developed for the treatment of chronic hepatitis B Virus infection.

Webull offers kinds of Benitec Biopharma Inc stock information, including NASDAQ:BNTC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BNTC stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BNTC stock methods without spending real money on the virtual paper trading platform.